Abbott and Novo Nordisk Join Forces to Combat Type 2 Diabetes in India
Abbott teams up with Novo Nordisk India to introduce Extensior, a second brand of Ozempic, aimed at treating type 2 diabetes in India. Utilizing Novo Nordisk's scientific expertise and Abbott's distribution strength, Extensior offers significant benefits including weight loss and cardiovascular risk reduction.
- Country:
- India
In a strategic collaboration, drug maker Abbott has partnered with Novo Nordisk India to commercialize Extensior, a variant of the diabetes medication Ozempic, designed to treat type 2 diabetes in India.
The initiative leverages Novo Nordisk's scientific leadership in GLP-1 treatment, alongside Abbott's extensive distribution network, to broaden access across the nation.
This partnership comes as India grapples with a burgeoning diabetes crisis, with cases expected to rise dramatically in the coming decades due to rapid urbanization and lifestyle changes.
Advertisement
ALSO READ
-
Novo Nordisk Slashes US Prices for Semaglutide Medicines
-
UPDATE 2-Novo Nordisk, United Laboratories 'triple G' drug trial shows 19.7% weight loss
-
UPDATE 1-Novo Nordisk, United Biotechnology obesity drug trial shows 19.7% weight loss
-
UPDATE 1-Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out
-
Novo Nordisk's CagriSema Underperforms: A Blow to Obesity Drug Market Dominance
Google News